Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 1NIH 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Neoplasms 2Ovarian Neoplasms 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Brain Neoplasms 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × cositecan × Clear all
NCT00062478 2020-03-12

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

BioNumerik Pharmaceuticals, Inc.

Phase 2 Completed
40 enrolled
CNS

Brain Neoplasms

NCT00062491 2020-03-12

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

BioNumerik Pharmaceuticals, Inc.

Phase 2 Completed
46 enrolled
Dermatologic

Melanoma, Neoplasms

NCT00097903 2020-03-12

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

BioNumerik Pharmaceuticals, Inc.

Phase 1 Completed
32 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT00477282 2020-03-12

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
509 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡